Comparison of IV Dexmedetomidine Versus Clonidine Versus no Alpha 2 Agonist on Emergency Delirium, PACU Length of Stay and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: a Prospective Observational Study (CLONIDEX)
Comparison of Intravenously Administered Dexmedetomidine Versus Clonidine Versus No Alpha-2 Agonist on Emergence Delirium, PACU Length of Stay, and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: A Prospective Observational Study
Emergence delirium (ED) is a frequent complication in children undergoing general anesthesia, particularly following ENT procedures such as adenotonsillectomy. Alpha-2 adrenergic agonists, such as clonidine and dexmedetomidine, are commonly used in pediatric anesthesia for their sedative, analgesic, and ED-reducing properties.The purpose of this prospective observational study (CLONIDEX) is to evaluate and compare the occurrence of emergence delirium, Post-Anesthesia Care Unit (PACU) length of stay, and overall time to hospital discharge in pediatric patients undergoing (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intravenous dexmedetomidine, intravenous clonidine, or no alpha-2 agonist as part of their standard anesthetic care.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Background:
Emergence delirium (ED) in pediatric patients leads to increased post-anesthesia care unit (PACU) complications, distress for parents and staff, and potential physical injury. While both clonidine and dexmedetomidine are widely utilized alpha-2 agonists in pediatric practice, real-world prospective comparative data regarding their relative efficacy on ED incidence and recovery timelines remain limited.
Study Design and Methodology This is a single-center, prospective observational cohort study conducted at UZ Brussel. Because this is an observational study evaluating standard-of-care practices, the administration and choice of alpha-2-agonist (IV dexmedetomidine, IV clonidine, or no alpha-2-agonist) are left entirely to the discretion of the attending pediatric anesthesiologist.
Data Collection and Outcomes:
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes will be observed. Key demographic data, anesthetic techniques, and intraoperative co-analgesics will be recorded. Upon arrival in the PACU, emergence delirium will be systematically assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale at set time intervals (arrival, 15, 30, 45, and 60 minutes). Secondary endpoints include PACU length of stay (measured against standardized discharge readiness criteria), total time to hospital discharge, requirement for rescue medication, and incidence of perioperative adverse events (such as postoperative nausea and vomiting, desaturation, or laryngospasm).
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Hélène De Cuyper, MD
- Número de teléfono: +3224749765
- Correo electrónico: helene.decuyper@uzbrussel.be
Copia de seguridad de contactos de estudio
- Nombre: Liza De Dobbeleer, Study Nurse
- Correo electrónico: liza.dedobbeleer@uzbrussel.be
Ubicaciones de estudio
-
-
Brussels Capital
-
Jette, Brussels Capital, Bélgica, 1090
- Universitair Ziekenhuis Brussel
-
Contacto:
- Hélène De Cuyper, MD
- Número de teléfono: +3224749765
- Correo electrónico: helene.decuyper@uzbrussel.be
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population consists of pediatric patients aged 2 to 12 years (ASA I-II) scheduled for elective ambulatory (adeno)tonsillectomy with or without placement of myringotomy tubes under general anesthesia at UZ Brussel. Participants are selected from the daily operating room list in the day-surgery unit.
Descripción
Inclusion Criteria:
- Children aged 2 to 12 years old.
- Scheduled for elective (adeno)tonsillectomy or tonsillectomy (with or without concurrent myringotomy/tympanostomy tube insertion).
- American Society of Anesthesiologists (ASA) physical status I or II.
- Surgery performed in an ambulatory / day-surgery setting under general anesthesia.
- Written informed consent provided by parents or legal guardians.
Exclusion Criteria:
- Known hypersensitivity or allergy to clonidine, dexmedetomidine, or other alpha-2 adrenergic agonists.
- Pre-existing severe cardiac conduction abnormalities, severe bradycardia, or hemodynamic instability.
- Severe neurodevelopmental impairment, severe cognitive impairment, or active central nervous system disorders that preclude reliable assessment using the PAED scale.
- Emergency tonsillectomy or active tonsillar hemorrhage.
- Patients requiring planned postoperative intensive care unit (PICU) admission or extended inpatient monitoring.
- Patient or parent/guardian refusal to participate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Dexmedetomidine Group
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intraoperative intravenous dexmedetomidine as part of standard anesthetic care, at the discretion of the attending anesthesiologist. |
Standard of care intraoperative intravenous administration of dexmedetomidine. Dose, timing, and administration are determined solely by the attending anesthesiologist. |
|
Clonidine Group
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intraoperative intravenous clonidine as part of standard anesthetic care, at the discretion of the attending anesthesiologist. |
Standard of care intraoperative intravenous administration of clonidine. Dose, timing, and administration are determined solely by the attending anesthesiologist. |
|
Control Group (No Alpha-2 Agonist)
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who do not receive any intraoperative alpha-2 adrenergic agonist (dexmedetomidine or clonidine) as part of standard anesthetic care. |
Standard anesthetic care during pediatric (adeno)tonsillectomy without administration of intraoperative alpha-2 adrenergic agonists. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence and Severity of Emergence Delirium (ED)
Periodo de tiempo: Assessed at PACU arrival (T0), and at 15 (T15), 30 (T30), 45 (T45), and 60 (T60) minutes post-operatively until PACU discharge.
|
Emergence delirium will be assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale. The PAED scale consists of 5 items, with total scores ranging from 0 to 20, where higher scores indicate greater severity of delirium. A PAED score >= 10 (or >= 12) is defined as the presence of emergence delirium. |
Assessed at PACU arrival (T0), and at 15 (T15), 30 (T30), 45 (T45), and 60 (T60) minutes post-operatively until PACU discharge.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Post-Anesthesia Care Unit (PACU) Length of Stay
Periodo de tiempo: From arrival at PACU until discharge readiness, assessed up to 2 hours post-operatively.
|
Time duration (in minutes) from arrival at the PACU until meeting formal criteria for discharge readiness (e.g., modified Aldrete or PADSS score). |
From arrival at PACU until discharge readiness, assessed up to 2 hours post-operatively.
|
|
Total Time to Hospital Discharge
Periodo de tiempo: From end of surgery until hospital discharge on Day 1 (up to 24 hours).
|
Time duration (in hours) from the end of anesthesia/surgery until actual discharge from the day-surgery clinic. |
From end of surgery until hospital discharge on Day 1 (up to 24 hours).
|
|
Incidence of Rescue Medication Administration
Periodo de tiempo: During the PACU stay, up to 2 hours post-operatively.
|
Proportion of patients requiring rescue medication in the PACU for severe emergence delirium or acute postoperative pain (e.g., propofol, opioids, or additional alpha-2 agonists). |
During the PACU stay, up to 2 hours post-operatively.
|
|
Incidence of Perioperative Adverse Events
Periodo de tiempo: From anesthesia induction until discharge from the day-surgery clinic (up to 24 hours).
|
Occurrence of airway or recovery complications including laryngospasm, oxygen desaturation (<92%), severe postoperative nausea and vomiting (PONV), or excessive sedation. |
From anesthesia induction until discharge from the day-surgery clinic (up to 24 hours).
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Hélène De Cuyper, MD, Department of Anesthesiology & Perioperative Medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Complicaciones Postoperatorias
- Procesos Patológicos
- Confusión
- Manifestaciones neuroconductuales
- Trastornos neurocognitivos
- Delirio
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Delirio de emergencia
- Dolor Postoperatorio
Otros números de identificación del estudio
Otros números de identificación del estudio
- CLONIDEX
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Patient Privacy & GDPR Compliance:
The study involves a vulnerable pediatric population. Full individual participant data sets, even if pseudonymized, carry a risk of re-identification when combined with detailed clinical and surgical variables, which violates strict European General Data Protection Regulation (GDPR) standards and institutional patient privacy policies.
Absence of Informed Consent for Broad Public Data Sharing:
The informed consent process and ethics committee approval approved for this study specifically cover data collection and analysis by the designated investigation team at UZ Brussel. Participants' legal guardians did not consent to open-access public repository sharing or secondary use of their children's raw individual data by external third parties.
Institutional & Regulatory Restrictions:
In accordance with hospital policy and national regulatory frameworks governing single-center observational clinical research, raw patient-level data remain restricted.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .